E Fund Management’s Vaxcyte PCVX Stock Holding History

E Fund Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$517K	Sell	8,898 -1,201	-12%	-$65.2K	0.01%	258
2026 Q1	$587K	Buy	+10,099	New	+$548K	0.02%	254
2025 Q2	$598K	Buy	18,398 +6,079	+49%	+$199K	0.03%	209
2025 Q1	$465K	Buy	12,319 +1,840	+18%	+$147K	0.02%	235
2024 Q4	$858K	Buy	10,479 +6,335	+153%	+$629K	0.04%	165
2024 Q3	$474K	Sell	4,144 -1,607	-28%	-$145K	0.02%	202
2024 Q2	$434K	Sell	5,751 -211	-4%	-$14.4K	0.02%	189
2024 Q1	$407K	Sell	5,962 -2,514	-30%	-$174K	0.03%	214
2023 Q4	$532K	Buy	8,476 +60	+0.7%	+$3.12K	0.03%	151
2023 Q3	$429K	Sell	8,416 -418	-5%	-$20.6K	0.03%	152
2023 Q2	$441K	Sell	8,834 -1,378	-13%	-$65.3K	0.03%	139
2023 Q1	$383K	Buy	10,212 +279	+3%	+$11.8K	0.03%	179
2022 Q4	$476K	Buy	+9,933	New	+$390K	0.04%	137

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

E Fund Management's PCVX Position: Q2 2026 in Review

E Fund Management reduced its Vaxcyte (PCVX) stake by 12% in Q2 2026, selling an estimated $65.2K and leaving 8,898 shares worth $517K. The position accounts for 0.01% of the portfolio, ranked #258.

E Fund Management first reported a position in PCVX in Q4 2022 and has held it in 13 quarters since. The position peaked at $858K in Q4 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

E Fund Management held 8,898 shares of Vaxcyte worth $517K as of Q2 2026.
E Fund Management sold 1,201 Vaxcyte shares in Q2 2026, an estimated $65.2K.
Vaxcyte made up 0.01% of E Fund Management's portfolio in Q2 2026, its #258 holding.
E Fund Management first reported a position in Vaxcyte in Q4 2022 and has held it in 13 quarters since.
E Fund Management's Vaxcyte position peaked at $858K in Q4 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.